Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

Core Insights - Frontier Medicines is advancing its lead candidates in collaboration with AbbVie, focusing on a key transcription factor for cancer cell survival, which has triggered a milestone payment [3] - The partnership aims to discover and develop innovative small molecule therapeutics targeting difficult-to-drug protein targets, with a focus on oncology and immunology [4][5] - Frontier's proprietary Frontier™ Platform utilizes covalent chemistry and machine learning to target hard-to-treat disease-causing proteins, with a diversified pipeline of precision medicines [2] Company Overview - Frontier Medicines is a clinical-stage precision medicine company that focuses on transforming treatment for genetically-defined patient populations, particularly in oncology and immunology [2] - The company’s lead candidate, FMC-376, is a dual inhibitor of ON+OFF KRASG12C, designed to block both forms of the KRAS mutation, addressing resistance seen with single-acting inhibitors [2] Partnership Details - Under the partnership with AbbVie, Frontier will collaborate on research and pre-clinical development, with AbbVie covering R&D costs through defined stages [5] - Frontier is eligible for success-based milestone payments that could exceed $1 billion, in addition to royalties on commercialized products [5] - AbbVie retains the right to expand the collaboration by exercising options for additional targets, while Frontier retains exclusive global rights to its internal programs [5]